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Abstract
Background: Adipokines are protein mediators secreted by adipose tissue. Recently, adipokines have also been
involved in the regulation of inflammation and allergic responses, and suggested to affect the risk of asthma
especially in obese female patients. We assessed if adipokines predict responsiveness to glucocorticoids and if
plasma adipokine levels are associated with lung function or inflammatory activity also in non-obese (body mass
index (BMI) ≤ 30 kg/m
2) women with newly-diagnosed steroid-naïve asthma.
Methods: Lung function, exhaled NO, plasma levels of adipokines leptin, resistin, adiponectin and adipsin, and
inflammatory markers were measured in 35 steroid-naïve female asthmatics and in healthy controls. The
measurements were repeated in a subgroup of asthmatics after 8 weeks of treatment with inhaled fluticasone.
Adipokine concentrations in plasma were adjusted for BMI.
Results: High baseline resistin concentrations were associated with a more pronounced decrease in serum levels
of eosinophil cationic protein (ECP) (r = -0.745, p = 0.013), eosinophil protein X (EPX) (r = -0.733, p = 0.016) and
myeloperoxidase (MPO) (r = -0.721, p = 0.019) during fluticasone treatment. In asthmatics, leptin correlated
positively with asthma symptom score and negatively with lung function. However, no significant differences in
plasma adipokine levels between non-obese asthmatics and healthy controls were found. The effects of resistin
were also investigated in human macrophages in cell culture. Interestingly, resistin increased the production of
proinflammatory factors IL-6 and TNF-a and that was inhibited by fluticasone.
Conclusions: High resistin levels predicted favourable anti-inflammatory effect of inhaled glucocorticoids
suggesting that resistin may be a marker of steroid-sensitive phenotype in asthma. High leptin levels were
associated with a more severe disease suggesting that the link between leptin and asthma is not restricted to
obesity.
Background
Asthma is a chronic inflammatory airway disease char-
acterised by cough, chest tightness and wheezing, and it
is associated with reversible or variable airway obstruc-
tion. However, the diagnosis and follow-up of the dis-
ease are currently based on symptoms and lung
function measurements rather than on assessing the
underlying inflammatory process [1]. Several asthmatic
phenotypes with different inflammatory mechanisms
have been described suggesting that asthma is not a sin-
g l ed i s e a s ee n t i t yb u tas y n d r o m ew i t hd i f f e r e n t
underlying causes and mechanisms [2]. The efficacy of
treatment with inhaled glucocorticoids seems to vary
between asthmatic phenotypes, and phenotype-specific
predictors of treatment response are needed.
Adipokines like leptin, adiponectin, resistin and adip-
s i na r ep r o t e i nm e d i a t o r ss ecreted by adipocytes and
macrophages within the adipose tissue [3]. Leptin and
resistin are usually pro-inflammatory, while adiponectin
has mainly anti-inflammatory properties [3]. Leptin
levels increase in obesity [4] and leptin has therefore
been suggested to belong to the factors explaining the
relation between obesity and asthma. Some studies sug-
gest that leptin affects asthma also independently of
body mass index (BMI) [5,6]. Adiponectin has been
demonstrated to have anti-inflammatory properties [3,7]
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regardless of BMI [8]. There are only a few publications
on resistin in human asthma with conflicting results
[9-11]. Larochelle et al [9] found higher resistin levels in
asthmatics and the levels were increased with disease
severity, while Kim et al [10] suggested that resistin may
have a protective effect against asthma. The role of adip-
sin in asthmatic inflammation has not been studied pre-
viously. There is limited data on adipokines in non-
obese asthmatics and only a little information how treat-
ment with inhaled glucocorticoids influence the circulat-
ing levels of adipokines.
A sd i s c u s s e da b o v e ,t h e r ea r es o m ee v i d e n c es u g g e s t -
ing connections between adipokines and asthma. How-
ever, further studies are needed to understand the role
of adipokines in the pathogenesis of, and more impor-
tantly, in predicting treatment responses in different
phenotypes of asthma. Nuclear factor B( N F - B) is a
transcription factor inducing the expression of many
pro-inflammatory genes. Inhaled glucocorticoids exert
their anti-inflammatory effects through a wide variety of
mechanisms, of which inhibition of NF-B is one of the
most important [12]. Interestingly, also adipokine resis-
tin has been linked to NF-kB at two levels; its expres-
sion is enhanced by inflammatory factors IL-1, IL-6,
TNF-a and LPS [13] which all are known activators of
NF-B. In addition, pro-inflammatory effects of resistin
are partly mediated through activation of the NF-B
p a t h w a y[ 1 4 ] .T h e r e f o r er e s i s t i nm a yh a v ear o l ea sa
factor or a predictor in steroid-responsive asthma.
T h ea i mo ft h ep r e s e n ts t u d yw a st oa s s e s si fp l a s m a
levels of resistin or other adipokines would predict the
responsiveness to inhaled corticosteroids, and if adipo-
kines are associated with lung function, symptoms or
inflammatory activity in newly diagnosed asthma in
non-obese (BMI ≤ 30 kg/m
2) female subjects. We found
that high baseline resistin levels predicted favourable
response to inhaled fluticasone, while high leptin levels
were associated with poor lung function and more
symptoms.
Methods
Subjects
Thirty-five steroid-naive, non-smoking female asth-
matics (mean age 34 yrs, range 20-57 yrs) with BMI ≤
30 kg/m
2 (range 18-30 kg/m
2) were recruited. The diag-
nosis of asthma was based on symptoms and reversible
or variable airway obstruction (b2-agonist induced
increase in FVC or FEV1 ≥ 12% and 200 ml, or diurnal
variability in PEF ≥20%, or exercise induced decrease in
FEV1 ≥ 15%). Thirty-two age- and sex-matched non-
smoking healthy controls with similar BMI, no asth-
matic symptoms and normal lung function served as
controls. Both groups were free from any other chronic
diseases.
Study protocol
Lung function, asthma symptom score, plasma levels of
adipokines, serum levels of other inflammatory markers,
and exhaled nitric oxide (NO) were measured in asth-
matics and in controls. The asthmatics also filled in an
asthma symptom questionnaire. The same measure-
ments were repeated in 11 asthmatics after 8 weeks of
treatment with inhaled fluticasone propionate (Flixotide
Diskus, GSK, Ware, UK, 500 μg b.i.d. during weeks 1-4,
and 250 μg b.i.d. during weeks 5-8). The study was
approved by the ethics committee of Tampere Univer-
sity Hospital and all subjects gave their written informed
consent.
Adipokines and inflammatory markers
Venous blood was collected for the assessment of
plasma levels of adipokines (resistin, leptin, adiponectin,
adipsin), serum levels of immunoglobulin E (IgE), eosi-
nophil cationic protein (ECP), eosinophil protein X
(EPX), myeloperoxidase (MPO), interleukin 6 (IL-6), and
blood eosinophil count (EOS). Adipokines were deter-
mined by enzyme-immuno-assay (EIA) by using com-
mercial reagents (DuoSet ELISA, R&D Systems Europe
Ltd, Abindgon, U.K). As plasma adipokine levels are
dependent on the amount of adipose tissue, adipokine
levels were adjusted for BMI by dividing the measured
concentration by BMI. Radioimmunoassay (ECP RIA,
EPX RIA and MPO RIA, Pharmacia AB, Uppsala, Swe-
den) was used to measure ECP, EPX and MPO levels.
Immunoluminometry was used to measure IgE, and IL-
6 was measured by EIA (PeliPair ELISA, Sanquin,
Amsterdam, Netherlands). The detection limits and
inter-assay coefficients of variation, respectively, were
15,6 ng/l and 4.0% for resistin, 15.6 ng/l and 3.9% for
leptin, 15.6 ng/l and 2.0% for adiponectin, 4.0 ng/l and
3.8% for adipsin, 2.0 μg/l and 4.2% for ECP, 3.0 μg/l and
5.4% for EPX, 8.0 μg/l and 6.2% for MPO and 0.6 ng/l
and 6.1% for IL-6.
Exhaled NO and lung function
Exhaled NO was measured with a Sievers NOA 280
®
NO-analyzer (Sievers Instruments, Boulder, CO, USA)
at exhalation flow rates of 100, 175 and 370 ml/s with a
mouth pressure of 9 cmH2O. The analyzer was cali-
brated daily with a known NO concentration (103 parts
per million (ppm), AGA, Sweden) and before every sub-
ject with filtered NO-free air. Bronchial NO flux and
alveolar NO concentration were calculated for each sub-
ject using the method described by Tsoukias and George
[15,16]. Airway function was measured with Vmax 20 C
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before and after 400 μg of inhaled salbutamol.
Asthma symptoms questionnaire
Asthma symptoms were recorded by using written
symptom questionnaire. Cough, chest tightness, wheez-
ing and nocturnal asthma symptoms were each scored
from 0 to 3 yielding a total score from 0 to 12 points
[17].
Cell culture
Human THP-1 monocyte/macrophage cell line (Ameri-
can Type Culture Collection, Manassas, VA, USA) was
used. The cells were cultured at 37°C in humidified 5%
carbon dioxide atmosphere in RPMI 1640 medium
adjusted to contain 2 mM L-glutamine, 10 mM HEPES,
1 mM sodium pyruvate, 4.5 g/l glucose, and 1.5 g/l
bicarbonate, and supplemented with 10% heat-inacti-
vated fetal bovine serum (all obtained from Lonza Ver-
viers SPRL, Belgium), penicillin (100 units/ml),
streptomycin (100 μg/ml) and amphotericin B (250 ng/
ml) (all obtained from Invitrogen, Paisley, UK), and 0.05
mM 2-mercaptoethanol. The cells were differentiated to
macrophages by adding the phorbol ester 12-O-tetrade-
canoylphorbol-13-acetate (TPA, 100 nM) for 72 h at the
time of seeding of the cells on 24-well plates. Cells were
serum starved for 16 h before the experiments were
started. Resistin (recombinant human resistin; Pepro-
Tech, Inc., Rocky Hill, NJ, USA) and fluticasone (Sigma
Chemical Co, St. Louis, MO, USA) were added in fresh
culture medium, and the cells were incubated for 24 h.
Culture medium was collected and stored at -20°C until
assayed. The concentrations of human IL-6 (PeliPair
ELISA, Sanquin, Amsterdam, Netherlands) and human
TNF-a (R&D Systems, Minneapolis, MN, USA) were
determined by ELISA. The detection limits and intra-
assay coefficients of variation, were 7.8 ng/l and 4.8% for
TNF-a and 0.6 ng/l and 6.0% for IL-6, respectively.
Statistics
Normality of the distributions of plasma adipokines and
other parameters were analysed with Kolmogorov-Smir-
nov’s test. Differences in adipokine levels between asth-
matics and controls were analysed with t-test or Mann-
Whitney test, where appropriate. Spearman’sr h ow a s
used to analyse correlations between adipokine levels
and lung function indices, other inflammatory markers
or symptom scores. Changes in plasma levels of adipo-
kines and other markers of inflammation during flutica-
sone treatment were analysed with a paired t-test or
Wilcoxon’s test, where appropriate. A stepwise multiple
linear regression analysis was used to determine if the
correlations between lung function indices and the levels
of plasma adipokines were explained by BMI. Results
from the cell culture experiments were analyzed by
using one-way ANOVA followed by Dunnett multiple
comparisons test. Results are presented as mean ± SEM
for normally distributed data and as median [interquar-
tile range] for non-normally distributed data. A p-value
< 0.05 was considered as significant. SPSS 15.0.1 soft-
ware (SPSS Inc., Chicago, Illinois, USA) was used in the
statistical analysis.
Results
Subject characteristics are given in Table 1. There were
no differences in age or BMI between asthmatics and
controls. Asthmatics had higher serum levels of EPX
and IgE, and higher blood eosinophil count and bron-
chial NO flux than controls.
Leptin and resitin levels were normally distributed,
while distribution of adiponectin and adipsin were non-
normal. As plasma adipokine levels are dependent on
the amount of adipose tissue, adipokine levels were
adjusted for BMI by dividing the measured concentra-
tion by BMI. There were no significant differences in
BMI-adjusted plasma adipokine levels between asth-
matics and healthy controls (Table 2).
Predicting treatment responses
Interestingly, pre-treatment resistin levels seemed to
predict the anti-inflammatory effect of inhaled flutica-
sone. Baseline BMI adjusted resistin correlated
Table 1 Subject characteristics.
Asthmatics Controls p-value
N3 5 3 2
Age (yrs) 33.9 ± 2.1 33.8 ± 2.1 0.980
BMI (kg/m
2) 23.1 ± 0.5 22.8 ± 0.5 0.627
FEV1(% pred) 90 ± 1.9 96 ± 3.2 0.125
ECP (μg/l) 11.2 [6.9 - 19.9] 9.2 [6.1 - 14.4] 0.105
EPX (μg/l) 29.6 [20.8 - 61.1] 18.3 [16.3 - 27.4] 0.003
MPO (μg/l) 218.6 [138.0 - 325.0] 246.8 [155.7 - 317.4] 0.716
EOS (10
9/l) 0.23 [0.16 - 0.44] 0.15 [0.10 - 0.20] <0.001
IgE (IU/l) 87.0 [25.0 - 204.0] 24.5 [11.0 - 41.0] 0.002
IL-6 (ng/l) 3.8 [2.6 - 5.3] 3.0 [2.3 - 5.0] 0.327
JBr,NO (nl/s) 2.6 ± 0.3 0.7 ± 0.1 <0.001
CAlv (ppb) 1.2 ± 0.3 1.1 ± 0.1 0.671
BMI, body mass index
FEV1, forced expiratory volume in 1 second
ECP, eosinophil cationic protein
EPX, eosinophil protein X
MPO, myeloperoxidase
EOS, blood eosinophil count
IgE, immunoglobulin E
IL-6, interleukin 6
JBr,NO, Bronchial NO flux
CAlv, Alveolar NO concentration
Values are presented as mean ± SEM for normally distributed data and as
median [interquartile range] for non-normally distributed data.
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-0.745, p = 0.013), EPX (rho = -0.733, p = 0.016, Figure
1), and MPO (rho = -0.721, p = 0.019, Figure 2) during
fluticasone treatment, i.e. the higher the pre-treatment
resistin the better the response to inhaled fluticasone.
The other adipokines did not correlate significantly
with fluticasone-induced changes in the inflammatory
markers.
Treatment with inhaled fluticasone decreased plasma
adipsin levels but had no effects on other adipokines.
Fluticasone treatment decreased also serum levels of
ECP and EPX, reduced bronchial NO flux and asthma
symptoms, and improved lung function (Table 3).
Correlations between adipokines and other parameters
In asthmatics, BMI adjusted leptin correlated positively
with asthma symptom score (rho = 0.371, p = 0.031)
and negatively with lung volumes VC% predicted (rho =
-0.445, p = 0.007), FVC% predicted (rho = -0.406, p =
0.016, Figure 3) and with FEV1% predicted (rho =
-0.345, p = 0.045, Figure 4), i.e. the higher the leptin
level, the poorer the lung function and the more symp-
toms. In contrast, BMI adjusted resistin correlated posi-
tively with lung volumes VC % predicted (rho = 0.383,
Table 2 Plasma levels of adipokines in asthmatics and
controls.
Asthmatics Controls p-value
N3 5 3 2
Resistin (ng/l)/BMI (m
2/kg) 0.5 [0.4 - 0.8] 0.5 [0.5 - 0.7] 0.603
Leptin (ng/l)/BMI (m
2/kg) 0.5 [0.5 - 1.1] 0.6 [0.4 - 0.8] 0.366
Adiponectin (ng/l)/BMI (m
2/kg) 165 ± 9.5 176 ± 13 0.490
Adipsin (ng/l)/BMI (m
2/kg) 32 ± 1.3 33 ± 1.3 0.813
Adipokine values were adjusted for BMI (body mass index)
Values are presented as mean ± SEM for normally distributed data and as
median [interquartile range] for non-normally distributed data.
Figure 1 Correlation between baseline resistin and fluticasone-
induced change in EPX. Baseline BMI-adjusted resistin correlated
negatively with the change in serum levels of eosinophil protein X
(EPX) during inhaled fluticasone treatment (Spearman’s rank
correlation), i.e. the higher the baseline resistin the larger the
decrease in EPX levels in response to inhaled fluticasone.
Figure 2 Correlation between baseline resistin and fluticasone-
induced change in MPO. Baseline BMI-adjusted resistin correlated
negatively with the change in serum levels of myeloperoxidase
(MPO) during inhaled fluticasone treatment (Spearman’s rank
correlation), i.e. the higher the baseline resistin the larger the
decrease in MPO levels in response to inhaled fluticasone.
Table 3 Plasma adipokines and other parameters before
and after 8-week treatment with fluticasone in 11
asthmatics.
Before
treatment
After
treatment
p-
value
Resistin (ng/l)/BMI (m
2/kg) 0.4 [0.3 - 0.5] 0.4 [0.4-0.5] 0.722
Leptin (ng/l)/BMI (m
2/kg) 0.5 [0.4 - 1.1] 0.7 [0.2-1.0] 0.722
Adiponectin (ng/l)/BMI
(m
2/kg)
154.4 ± 20.1 146.4 ± 21.0 0.271
Adipsin (ng/l)/BMI (m
2/kg) 27.5 ± 1.5 24.9 ± 1.8 0.026
ECP (μg/l) 16.0 [8.5 - 46.8] 12.4 [6.2 - 21.4] 0.026
EPX (μg/l) 47.2 [28.8 - 68.4] 22.3 [16.6 - 45.1] 0.013
MPO (μg/l) 218.6 [163.5 -
409.1]
199.7 [144.7 -
266.8]
0.534
FEV1(% pred) 85 ± 4.0 95 ± 5.5 0.032
JBr,NO (nl/s) 3.6 ± 0.4 0.6 ± 0.1 <0.001
CAlv (ppb) 1.5 ± 0.6 1.3 ± 0.1 0.705
Symptom score 6.0 [4.0 - 10.0] 0 [0.0 - 0.0] 0.005
ECP, eosinophil cationic protein
EPX, eosinophil protein X
MPO, myeloperoxidase
FEV1, forced expiratory volume in 1 second
JBr,NO, Bronchial NO flux
CAlv, Alveolar NO concentration
Adipokine values were adjusted for BMI (body mass index).
Values are presented as mean ± SEM for normally distributed data and as
median [interquartile range] for non-normally distributed data.
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0.008) in asthmatics. Adiponectin and adipsin had no
correlations with indices of lung function, symptoms or
serum markers of inflammation.
As both lung function and plasma adipokines are
related to BMI, we tested if the above mentioned corre-
lations between adipokines and lung function are
e x p l a i n e db yB M I .W ec o n d u c t e das t e p w i s em u l t i p l e
linear regression analysis with lung function as the
dependent variable, and BMI and adipokine levels as
independent variables. Correlation of BMI adjusted
resistin with VC % predicted and FVC % predicted were
explained by changes in BMI. However, BMI adjusted
leptin was an independent predictor of VC % predicted,
FVC % predicted and FEV1 % predicted.
The effects of resistin on IL-6 and TNFa production in
human macrophages
Because resistin levels were associated with favourable
anti-inflammatory activity of fluticasone, we studied the
effects of this adipokine on human THP-1 macrophages.
Interestingly, resistin (0.1 - 2 μg/ml) increased production
of proinflammatory cytokines IL-6 and TNF-a in THP-1
cells in a concentration-dependent manner. Moreover,
fluticasone (10 and 100 nM) significantly reduced resis-
tin-induced IL-6 and TNF-a production in (Figure 5).
Discussion
In the present study, we investigated the role of adipo-
kines in asthma in non-obese steroid-naive female
patients. The main finding was that high pre-treatment
resistin levels were associated with a more pronounced
decrease in serum levels of inflammatory markers dur-
ing fluticasone treatment indicating a better steroid-
response. In addition, high plasma leptin levels were
associated with poorer lung function and increased
symptoms suggesting that leptin is related to the sever-
ity of asthma also in non-obese patients.
Resistin is associated with different inflammatory states
[3], but there are only a few previous publications on
resistin in patients with asthma. LaRochelle et al showed
that steroid-treated patients with moderate to severe
asthma had higher levels of resistin than controls, and
resistin levels were increased with increasing disease
severity [9]. On the contrary, Kim and colleagues found
that resistin levels were lower in atopic asthmatic chil-
dren than in healthy controls, and resistin was associated
with lower markers of atopy or bronchial responsiveness
[10]. However, Arshi et al did not find any differences in
resistin levels between pediatric patients with asthma and
healthy children [11]. In the present study including non-
obese women with newly diagnosed steroid-naïve asthma,
we found that baseline resistin concentrations correlated
with anti-inflammatory effects of inhaled fluticasone sug-
gesting that resistin may be a feature and biomarker of
steroid-sensitive phenotype of asthma. This relation may
be explained by the finding that resistin is an endogenous
agonist of Toll-like receptor 4 (TLR4) which leads to acti-
vation of various genes involved in asthmatic inflamma-
tion through NF-kB pathway [18]. Accordingly, we found
here that resistin was able to enhance the production of
proinflammatory cytokines IL-6 and TNF-a in human
macrophages and interestingly, this effect was inhibited
with fluticasone. Also, the expression of resistin itself has
Figure 3 Correlation between leptin and FVC in steroid-naïve
asthmatics. BMI-adjusted plasma concentrations of leptin correlated
negatively with forced vital capacity (FVC, % predicted) in
asthmatics (Spearman’s rank correlation), i.e. the higher the BMI
adjusted leptin level the lower the FVC (% predicted).
Figure 4 Correlation between leptin and FEV1 in steroid-naïve
asthmatics. BMI-adjusted plasma concentrations of leptin correlated
negatively with forced expiratory volume in 1 second (FEV1,%
predicted) in asthmatics (Spearman’s rank correlation), i.e. the higher
the BMI adjusted leptin level the lower the FEV1 (% predicted).
Leivo-Korpela et al. Journal of Inflammation 2011, 8:12
http://www.journal-inflammation.com/content/8/1/12
Page 5 of 7been reported to be enhanced by inflammatory factors
like IL-1, IL-6, TNF-a and LPS by an NF-B dependent
manner [13,14]. Therefore high resistin levels may reflect
an asthmatic phenotype characterized by increased NF-
B activity and hence favourable response to glucocorti-
coids, the anti-inflammatory action of which is primarily
based on their suppressive effect on NF-B [12].
We found that in non-obese female asthmatics the
levels of adipokines were not different from healthy con-
trols. Previously, conflicting results on the levels of adi-
pokines in patients with asthma have been published.
Leptin has been reported to be increased [5,6,19,20] or
normal [10,21,22] in asthma, resistin either increased [9]
or decreased [10], and adiponectin either decreased
[8,23] or normal [10,21,22]. There are no previous pub-
lications on adipsin in asthma. The conflicting results
are likely explained by differences in patient selection.
Asthma is often considered as a single disease entity,
but it is actually a syndrome with many different patho-
logical pathways ultimately leading to quite similar clini-
cal presentation: variable airway obstruction with chest
tightness, wheezing and cough [2]. The role of adipo-
kines quite likely varies between these different inflam-
matory processes. In addition, there are patient-related
contributing factors like age, sex, fat distribution in the
body, menopause, atopy, comorbidities and drugs, but
there is insufficient data on the detailed effects, mechan-
isms and significance of these factors so far.
Interestingly, BMI-adjusted leptin levels were associated
with poorer lung function and more symptoms in the
present study in non-obese steroid-naïve asthmatics. This
is in line with a previous study showing an inverse
correlation between leptin levels and lung function in
non-obese healthy subjects [24] suggesting that leptin is
associated with lung function regardless of BMI. Leptin
has been reported to induce the production of pro-
inflammatory mediators TNF-a,I L - 6a n dI L - 1 2[ 2 5 ] .
This may further augment asthmatic inflammation and
might explain the association of leptin to asthma severity.
We also found that inhaled glucocorticoids decreased
plasma levels of adipsin but had no effect on other adi-
pokines. This may be explained by the previous finding
that glucocorticoids down-regulate the expression of
adipsin gene [26]. In line with the negative effect of flu-
ticasone on leptin in the present study, Radetti’sa n d
Heuck’sg r o u p sh a v er e p o r t e dp r e v i o u s l yt h a tl e p t i n
secretion was not affected by inhaled corticosteroids
[27,28]. However, there are no previous studies on the
effect of inhaled glucocorticoids on the levels of other
adipokines than leptin.
Conclusions
In non-obese women with newly-diagnosed steroid-
naïve asthma, high resistin levels predicted favourable
anti-inflammatory effect of inhaled glucocorticoids sug-
gesting that resistin may be a feature and biomarker of
steroid-sensitive phenotype of asthma. High leptin levels
were associated with a more se v e r ea s t h m as u g g e s t i n g
that the link between adipokine leptin and asthma is not
restricted to obesity.
Figure 5 Resistin enhanced cytokine production in human macrophages, and that was reversed by fluticasone.H u m a nT H P - 1
macrophages were cultured for 24 h with resistin (2 μg/ml) in the absence and in the presence of fluticasone (10 - 100 nM). Thereafter
interleukin-6 (IL-6, A) and tumor necrosis factor alpha (TNFa, B) concentrations were measured in the culture media by ELISA. Results are
expressed as mean ± SEM.
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